Ventyx Biosciences, Inc. VTYX
Set alert
As of Mar 6, 9:30 AM ET
52-week range unavailable
- YTD
- +55.04%
- 1 year
- +858.90%
- Open
- 14.00
- Prev close
- 14.00
- Mkt cap
- 1.00B
- Vol
- 5.40M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 14.00
- High
- 14.00
- Beta
- 1.27
- Inst. own
- 84.50%
- Dividend
- 0.00
- Earnings
- Mar 5, 2026
2Y chart
Events in this range
- Nov 7, 2024Earnings: -0.5; estimate -0.48; surprise -4.17%
- Feb 27, 2025Earnings: -0.41; estimate -0.54; surprise 24.07%
- May 8, 2025Earnings: -0.39; estimate -0.48; surprise 18.75%
- Aug 7, 2025Earnings: -0.38; estimate -0.45; surprise 15.56%
- Nov 6, 2025Earnings: -0.32; estimate -0.45; surprise 28.89%
- Jan 8, 2026Downgrade: Canaccord Genuity · Buy → Hold
- Jan 8, 2026Downgrade: LifeSci Capital · Outperform → Market Perform
- Jan 8, 2026Downgrade: UBS · Buy → Neutral
- Jan 8, 2026Downgrade: HC Wainwright & Co. · Buy → Neutral
- Jan 8, 2026Downgrade: Wells Fargo · Overweight → Equal-Weight
- Jan 8, 2026Downgrade: Oppenheimer · Outperform → Perform
- Mar 5, 2026Earnings: —; estimate -0.38627; surprise —%
Signals (81)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Jan 27, 2026 | 9 months ago |
| RSI: Overbought | Jan 7, 2026 | 9 months ago |
| SMA: Bullish | Jan 6, 2026 | 10 months ago |
| MACD: Buy Signal | Jan 6, 2026 | 10 months ago |
| SMA: Bearish | Jan 2, 2026 | 10 months ago |
| MACD: Sell Signal | Jan 2, 2026 | 10 months ago |
| MACD: Buy Signal | Dec 24, 2025 | 10 months ago |
| RSI: Overbought | Nov 24, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 17, 2025 | 11 months ago |
| MACD: Buy Signal | Oct 23, 2025 | 1 year ago |
| RSI: Overbought | Oct 23, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 21, 2025 | 1 year ago |
| RSI: Overbought | Oct 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Aug 21, 2025 | 1 year ago |
| SMA: Bullish | Aug 8, 2025 | 1 year ago |
| SMA: Bearish | Aug 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 29, 2025 | 1 year ago |
Newest 20 of 81.
Key statistics
- Market cap
- 1.00B
- Enterprise value
- 982.56M
- Trailing P/E
- -20.00
- PEG ratio
- -0.41
- Price / sales
- 0.00
- Price / book
- 5.22
- Beta
- 1.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -24.86%
Analyst view
- Strong buy0
- Buy0
- Hold5
- Sell0
- Strong sell0
Next earnings
Mar 5, 2026
Expected Mar 5, 2026. Consensus EPS estimate -0.39441.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 5, 2026 | Dec 30, 2025 | -0.38627 | — | — | — |
| Nov 6, 2025 | Sep 30, 2025 | -0.45 | -0.32 | +0.13 | +28.89% |
| Aug 7, 2025 | Jun 30, 2025 | -0.45 | -0.38 | +0.07 | +15.56% |
| May 8, 2025 | Mar 31, 2025 | -0.48 | -0.39 | +0.09 | +18.75% |
| Feb 27, 2025 | Dec 31, 2024 | -0.54 | -0.41 | +0.13 | +24.07% |
| Nov 7, 2024 | Sep 30, 2024 | -0.48 | -0.50 | -0.02 | -4.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 8, 2026 | Oppenheimer | down | Outperform | Perform |
| Jan 8, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Jan 8, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Jan 8, 2026 | UBS | down | Buy | Neutral |
| Jan 8, 2026 | LifeSci Capital | down | Outperform | Market Perform |
| Jan 8, 2026 | Canaccord Genuity | down | Buy | Hold |
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary investigational drug, VTX958, a tyrosine kinase type 2 (TYK2) inhibitor, is currently undergoing Phase I clinical trials. This compound aims to address a range of immune-mediated conditions, including psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. Among its pipeline assets is VTX002, an oral sphingosine 1 phosphate receptor 1 (S1P1) modulator, which has advanced to Phase II clinical studies for the treatment of ulcerative colitis. Additionally, VTX2735, a peripherally targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor, is in Phase I development, intended to combat systemic inflammatory diseases affecting cardiovascular, hepatic, renal, and rheumatologic systems. Furthermore, Ventyx is engaged in the development of CNS-penetrant NLRP3 inhibitors, with the objective of providing therapies for neurological ailments such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Founded in 2018, Ventyx Biosciences, Inc. is headquartered in Encinitas, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 81
- Website
- lilly.com
News
- Eli Lilly Expands Into Sleep Medicine With Centessa Buyout
- Alphabet To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Thursday
- Crude Oil Down 2%; ISM Services PMI Surges In December
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
- Market-Moving News for January 7th
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Why Penguin Solutions Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on VTYX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AUSTER MARTIN | Chief Financial Officer | Sale | Apr 1, 2024 | 24,303 |
| FORMAN MARK S M.D., PH.D. | Officer | Stock Award(Grant) | Nov 16, 2025 | 6,000 |
| GONZALES ROY M. | Officer | Stock Award(Grant) | Nov 16, 2025 | 5,313 |
| GUJRATHI SHEILA | Director | Purchase | Dec 22, 2024 | 0 |
| KRUEGER CHRISTOPHER W | Officer | Sale | Apr 1, 2024 | 284,999 |
| MOHAN RAJU | Chief Executive Officer | Sale | Dec 17, 2025 | 2,372,860 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Affinity Asset Advisors, Llc | 9.04% | 6,484,558 | 90.78M | Dec 30, 2025 |
| Morgan Stanley | 5.98% | 4,292,951 | 60.10M | Dec 30, 2025 |
| Vanguard Group Inc | 5.50% | 3,943,566 | 55.21M | Dec 30, 2025 |
| Blackrock Inc. | 4.38% | 3,142,440 | 43.99M | Dec 30, 2025 |
| Tang Capital Management, LLC | 3.92% | 2,814,000 | 39.40M | Dec 30, 2025 |
| Baker Bros. Advisors, LP | 3.27% | 2,349,280 | 32.89M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.81% | 2,014,966 | 28.21M | Dec 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.97% | 694,497 | 9.72M | Dec 30, 2025 |
| BlackRock Funds-BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO | 0.84% | 603,440 | 8.45M | Nov 29, 2025 |
| iShares Trust-iShares Biotechnology ETF | 0.66% | 472,766 | 6.62M | Dec 30, 2025 |
| Delaware Group Equity Funds IV-Nomura Healthcare Fund | 0.60% | 430,000 | 6.02M | Dec 30, 2025 |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund | 0.57% | 409,356 | 5.73M | Dec 30, 2025 |